Publications
Download CSV
Download XLSX
Download TXT
Tables
2026 (153)
2025 (1341)
2024 (1338)
2023 (1293)
2022 (1414)
2021 (1441)
2020 (1232)
2019 (1092)
2018 (1152)
2017 (1039)
2016 (939)
2015 (693)
2014 (622)
2013 (473)
2012 (344)
2011 (199)
2010 (72)
2009 (38)
2008 (39)
2007 (13)
2006 (19)
2005 (9)
2004 (3)
2003 (2)
2002 (1)
All (14961)
Labels
Labels list
Labels table
Researchers
Subset
Documentation
About
Contact
Software
Login
Pharmacogenomics
JSON
ISSN
1744-8042
ISSN-L
1462-2416
IUID
b8f13b2224bf45828ac3fff866e05793
Modified
2020-11-27T13:12:56.732Z
Created
2018-12-05T11:20:04.638Z
Year 2025
PubMed
DOI
Crossref
Machine learning models for pharmacogenomic variant effect predictions - recent developments and future frontiers.
Tremmel R, Honore A, Park Y, ..., Xiao M, Lauschke VM
Pharmacogenomics
26
(5-6) 171-182 [2025-05-22; online 2025-05-22]
DDLS Fellow
Yitian Zhou
Year 2022
PubMed
DOI
Crossref
Genome-wide association study of liver enzyme elevation in an extended cohort of rheumatoid arthritis patients starting low-dose methotrexate.
Cavalli M
,
Eriksson N
,
Sundbaum JK
, ...,
Hallberg P
,
Wadelius M
Pharmacogenomics
23
(15) 813-820 [2022-10-00; online 2022-09-07]
Year 2021
PubMed
DOI
Crossref
Genome-wide association study of liver enzyme elevation in rheumatoid arthritis patients starting methotrexate.
Sundbaum JK
, Baecklund E,
Eriksson N
, ...,
Wadelius M
,
Hallberg P
Pharmacogenomics
22
(15) 973-982 [2021-10-00; online 2021-09-15]
Year 2020
PubMed
DOI
Crossref
Impact of variants in ATP-binding cassette transporters on breast cancer treatment.
Xiao Q
, Zhou Y,
Lauschke VM
Pharmacogenomics
21
(18) 1299-1310 [2020-12-00; online 2020-11-23]
DDLS Fellow
Yitian Zhou
PubMed
DOI
Crossref
MTHFR, TYMS and SLCO1B1 polymorphisms and adverse liver effects of methotrexate in rheumatoid arthritis.
Sundbaum JK
, Baecklund E, Eriksson N, ..., Kohnke H,
Wadelius M
Pharmacogenomics
21
(5) 337-346 [2020-04-00; online 2020-02-06]
Year 2019
PubMed
DOI
Crossref
CYP3A5 is unlikely to mediate anticancer drug resistance in hepatocellular carcinoma.
Lauschke VM
, Nordling Å, Zhou Y, ..., Barragan I, Ingelman-Sundberg M
Pharmacogenomics
20
(15) 1085-1092 [2019-10-00; online 2019-10-08]
DDLS Fellow
Yitian Zhou
Year 2017
PubMed
DOI
Crossref
Genetic variants associated with angiotensin-converting enzyme inhibitor-induced cough: a genome-wide association study in a Swedish population.
Hallberg P, Persson M, Axelsson T, ..., Eriksson N, Wadelius M
Pharmacogenomics
18
(3) 201-213 [2017-02-00; online 2017-01-13]
Year 2016
PubMed
DOI
Crossref
Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy.
Eriksson N, Wallentin L, Berglund L, ..., Yusuf S, Wadelius M
Pharmacogenomics
17
(13) 1425-1439 [2016-08-00; online 2016-08-04]
PubMed
DOI
Crossref
Novel regulatory variant detected on the VKORC1 haplotype that is associated with warfarin dose.
Cavalli M, Pan G, Nord H, ..., Wadelius C, Wadelius M
Pharmacogenomics
17
(12) 1305-1314 [2016-08-00; online 2016-02-05]
Year 2015
PubMed
DOI
Crossref
Genome-wide association study of warfarin maintenance dose in a Brazilian sample.
Parra EJ, Botton MR, Perini JA, ..., Hutz MH, Suarez-Kurtz G
Pharmacogenomics
16
(11) 1253-1263 [2015-08-12; online 2015-08-12]
Year 2011
PubMed
DOI
Crossref
Microtubule-targeting drugs and personalization of cancer treatment.
Rodríguez-Antona C, Gréen H
Pharmacogenomics
12
(4) 449-451 [2011-04-00; online 2011-04-28]
SciLifeLab Data Centre
Publications
9.5.2